Jin Mei, Zhang Dawei, Zhao Qian, Zhao Wen, Huang Cheng, Wang Xisi, Duan Chao, Su Yan, Ma Xiaoli
Beijing Key Laboratory of Pediatric Hematology Oncology; National Discipline of Pediatrics, Ministry of Education; MOE Key Laboratory of Major Diseases in Children; Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Medicine (Baltimore). 2020 Jun 26;99(26):e20896. doi: 10.1097/MD.0000000000020896.
Metastatic neuroblastoma (NB) is an aggressive malignancy with a poor prognosis. Many patients present with relapsed high-risk NB after undergoing first-line treatment, and there is no standard therapy available in this setting.
The present study aimed to present the cases of 2 patients with recurrent high-risk NB.
Two children with International Neuroblastoma Stage System stage 4 high-risk NB chemotherapy. The disease recurrent after finishing the treatment.
Both patients (34 months old and 41 months old) experienced recurrence, received second-line treatment, and then received maintenance treatment using apatinib plus retinoic acid. The apatinib (10 mg/kg per day) and retinoic acid (160 mg/m per day) were administered on alternating 2-week cycles, which was continued for 1 year.
The 2 patients had achieved complete response by the 1-year follow-up after starting apatinib plus retinoic acid, and did not experience any adverse drug reactions.
The outcomes from these cases suggest that apatinib plus isotretinoin might be an option for maintenance therapy in patients with recurrent high-risk NB.
转移性神经母细胞瘤（NB）是一种侵袭性恶性肿瘤，预后较差。许多患者在接受一线治疗后出现复发性高危NB，在此情况下尚无标准治疗方法。
本研究旨在介绍2例复发性高危NB患者的病例。
两名儿童患有国际神经母细胞瘤分期系统4期高危NB并接受化疗。治疗结束后疾病复发。
两名患者（分别为34个月和41个月大）均出现复发，接受二线治疗，然后接受阿帕替尼加维甲酸的维持治疗。阿帕替尼（每日10mg/kg）和维甲酸（每日160mg/m）每2周交替给药一次，持续1年。
2例患者在开始阿帕替尼加维甲酸治疗1年后的随访中达到完全缓解，且未出现任何药物不良反应。
这些病例的结果表明，阿帕替尼加异维甲酸可能是复发性高危NB患者维持治疗的一种选择。
